Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 359 | 55 | 301 |
| Samples | 225 | 41 | 182 |
| Peptides | 209 | 30 | 182 |
Function
GPX6 · Glutathione peroxidase 6
The protein encoded by this gene belongs to the glutathione peroxidase family, members of which catalyze the reduction of hydrogen peroxide, organic hydroperoxides and lipid hydroperoxides, and thereby protect cells against oxidative damage. Several isozymes of this gene family exist in vertebrates, which vary in cellular location and substrate specificity. Expression of this gene has been observed in embryos and olfactory epithelium; however, the exact function of this gene is not known. This isozyme is a selenoprotein in humans, containing the rare amino acid selenocysteine (Sec) at its active site. Sec is encoded by the UGA codon, which normally signals translation termination. The 3' UTRs of selenoprotein mRNAs contain a conserved stem-loop structure, designated the Sec insertion sequence (SECIS) element, that is necessary for the recognition of UGA as a Sec codon, rather than as a stop signal. The orthologs of this gene in mouse and rat (and some other species) contain a cysteine (Cys) residue in place of the Sec residue, and their corresponding mRNAs lack SECIS element. [provided by RefSeq, Jul 2017].
Isoforms & Proteins
2 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000361902 | P59796 | 204 | 158 |
| ENST00000474923 | - | 155 | 117 |
Gene Properties
Recurrent Mutations
All 158 amino-acid changes on canonical ENST00000361902 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in GPX6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in GPX6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Melanoma | 8/210 4% | 57/1899 3% |
| Thymic Epithelial Tumor | 0/0 0% | 1/39 3% |
| Endometrial Carcinoma | 5/42 12% | 10/612 2% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 10/810 1% |
| Other Solid Cancers | 2/94 2% | 17/1515 1% |
| Small Cell Lung Carcinoma | 0/9 0% | 8/752 1% |
| Non-Small Cell Lung Carcinoma | 5/304 2% | 11/1390 1% |
| Gastric Carcinoma | 0/74 0% | 17/1809 1% |
| Cervical Carcinoma | 2/35 6% | 2/422 0% |
| Bladder Carcinoma | 3/58 5% | 3/956 0% |
| Colorectal Carcinoma | 3/143 2% | 13/3239 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Ovarian Carcinoma | 0/109 0% | 5/998 0% |
| Burkitts Lymphoma | 0/32 0% | 1/196 1% |
| Hepatocellular Carcinoma | 1/46 2% | 8/2210 0% |
| Head and Neck Carcinoma | 1/85 1% | 5/1574 0% |
| Neuroendocrine Tumour | 0/154 0% | 2/577 0% |
| Other Sarcomas | 2/69 3% | 0/699 0% |
| Prostate Carcinoma | 2/13 15% | 2/2105 0% |
| Neuroblastoma | 1/87 1% | 1/1331 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 2/2550 0% |
| Breast Carcinoma | 1/144 1% | 1/3264 0% |
| Kidney Carcinoma | 0/85 0% | 1/1862 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 1/2534 0% |
| Other Blood Cancers | 1/61 2% | 0/2725 0% |
Mutation Distribution
Where GPX6 is mutated · all tissues, split by cell line vs tissue
How many mutations in GPX6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 2 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 359 mutations in GPX6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|